Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Managing obesity in people who also have type 2 diabetes presents unique clinical challenges, as both conditions interact to worsen metabolic health. The SURMOUNT-2 trial by Garvey, Frias, Jastreboff, and colleagues, published in The Lancet, evaluated tirzepatide specifically in this dual-diagnosis population.

This double-blind, randomized, multicentre, placebo-controlled phase 3 trial enrolled people with both obesity and type 2 diabetes to assess tirzepatide's once-weekly treatment effects on body weight and glycemic control. The rigorous trial design provided high-quality evidence for clinical decision-making.

The SURMOUNT-2 trial demonstrated significant weight loss with tirzepatide while simultaneously improving glycemic control in people with both obesity and type 2 diabetes. These dual metabolic benefits confirm that tirzepatide addresses the interconnected nature of these conditions rather than treating them in isolation.

For the many patients who struggle with the compounding effects of obesity and type 2 diabetes, this trial provides strong evidence that tirzepatide can meaningfully improve both conditions with a single therapy. This dual-benefit approach simplifies treatment regimens and may lead to better long-term metabolic health outcomes.